Stuart D. Russell, MD
Professor of Medicine
Duke University School of Medicine
Regional Director of Heart Failure
Duke University Medical Center
Additional Content Development Faculty
Biykem Bozkurt, MD, PhD
Professor of Medicine
The Mary and Gordon Cain Chair & W.A. "Tex" and Deborah Moncrief, Jr., Chair
Vice-Chair, Department of Medicine Baylor College of Medicine
Associate Director, Cardiovascular Research Institute
Director, Winters Center for Heart Failure Research
Baylor College of Medicine
Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program
Co-Chief UCLA Division of Cardiology
The Eliot Corday Chair in Cardiovascular Medicine and Science
Los Angeles, CA
In the United States, heart failure (HF) affects about 5.7 million adults, accounts for >1 million hospitalizations annually, and is the leading cause of hospitalization for adults >65 years of age. Despite diagnostic and therapeutic advances in the last several decades and improved survival rates, roughly 50% of people with HF die within 5 years of diagnosis. Rates of cardiovascular death or HF-related hospitalization are greatest for people who have been previously hospitalized for HF, particularly older adults. All clinicians who encounter patients with HF have a role to play in improving patients’ health-related quality of life while reducing symptoms, hospitalizations, and mortality. This case-based presentation will examine in-hospital management, transition after hospital discharge, and initiation of guideline-directed medical therapy (GDMT) for outpatient care.
Cardiologists, emergency medicine physicians, hospitalists, internal medicine and primary care physicians, nurse practitioners (NPs), physician assistants (PAs), nurses, and other clinicians who care for patients with HF.
Upon completion of this educational activity, the participant should be able to:
- Describe the most recent evidence-based guidelines for the management of HF in the hospital, during transition from in-hospital to outpatient, and in outpatient settings, including the role of newly approved agents.
- Create individualized plans for managing patients with acute HF and transitioning these patients from the hospital to an outpatient situation.
- Create individualized plans for managing patients with HF in the outpatient setting.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Dr. Russell has nothing to disclose.
Dr. Bozkurt has nothing to disclose.
Dr. Fonarow has disclosed the following:
Consultant/Advisor: Amgen, Janssen, Medtronic, Novartis, US Pharma
Penn State staff involved in the development and review of this activity have nothing to disclose.
MCM Education staff involved in the development and review of this activity have nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6128-18-T.
Commercial Support Statements
Supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; or Novartis Pharmaceuticals Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.